Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2024-05-30T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, sec

TL;DR

Catalyst Pharma filed a routine 8-K, no new info yet.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on May 30, 2024, to report other events and financial statements. The filing does not contain specific details on new events or financial figures but serves as a standard regulatory update.

Why It Matters

This filing indicates Catalyst Pharmaceuticals is meeting its regulatory reporting obligations with the SEC. It does not contain new material information for investors at this time.

Risk Assessment

Risk Level: low — The filing is a standard regulatory document and does not disclose any new material risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 30, 2024.

What specific 'Other Events' are detailed in this filing?

The provided text of the 8-K filing does not detail specific 'Other Events'; it only indicates that this item is being reported.

Are there any new financial statements or exhibits included with this filing?

The filing indicates that 'Financial Statements and Exhibits' are being reported, but the specific content of these is not detailed in the provided header information.

When was Catalyst Pharmaceuticals, Inc. incorporated?

Catalyst Pharmaceuticals, Inc. was incorporated in Delaware.

What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?

The principal executive office address is 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.

From the Filing

0001193125-24-150433.txt : 20240530 0001193125-24-150433.hdr.sgml : 20240530 20240530164302 ACCESSION NUMBER: 0001193125-24-150433 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240530 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 241006156 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d831301d8k.htm FORM 8-K Form 8-K NASDAQ false 0001369568 0001369568 2024-05-30 2024-05-30     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On May 30, 2024, the Company issued a press release announcing that the U.S. Food and Drug Administration has approved its supplemental New Drug Application increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome. A copy of the press re

View on Read The Filing